Tardive dyskinesia (TD) presents a significant challenge, often arising from the extended use of antipsychotic drugs like Abilify. Effective treatments such as Austedo and FDA-approved options aim to manage symptoms and improve quality of life. Understanding these options, alongside prevention strategies, is vital for both patients and healthcare providers navigating TD’s complexities.
Understanding Tardive Dyskinesia
Tardive dyskinesia (TD) is a challenging movement disorder that originates from the prolonged use of neuroleptic or antipsychotic medications. These drugs are commonly prescribed for managing psychiatric and neurological disorders. The disorder leads to involuntary movement issues, which can significantly impact a person’s daily life and overall quality of life with frequent disruptions. The severity and onset of TD can depend on the type of drug used, how long it has been used, and the dosage levels maintained over time.
Abilify and Its Role in Tardive Dyskinesia
Abilify (aripiprazole) is an atypical antipsychotic that plays a distinct role in treating psychiatric conditions. Despite its advantages as a newer antipsychotic agent, Abilify can still be linked to TD, though it is less likely compared to traditional antipsychotics. It is crucial for healthcare providers to monitor patients on Abilify rigorously, looking out for early symptoms of TD. This constant vigilance allows for timely intervention and helps reduce the duration and severity of TD symptoms.
Treating Tardive Dyskinesia with Austedo
Austedo (deutetrabenazine) stands out as an effective treatment option for managing TD symptoms. Introduced as a crucial medication in 2017, Austedo works by reducing dopamine signaling. This mechanism is significant as it alleviates the involuntary movements typical of the disorder. Clinical studies have demonstrated Austedo’s ability to improve symptoms rapidly, sometimes within just two weeks of beginning treatment. The convenient once-daily pill ensures patient compliance and simplifies treatment regimens, especially for those also dealing with Huntington’s disease chorea alongside TD.
FDA-Approved Treatments and their Efficacy
In recent years, comprehensive treatment choices for TD have expanded significantly. The FDA has approved various medications like Ingrezza (valbenazine) alongside Austedo. These medications provide a solid first-line defense, aiming to control symptoms effectively by targeting the same dopamine pathways linked to involuntary movements. The advancement of treatments has offered renewed hope for TD sufferers, highlighting a move toward more nuanced and effective management of the disorder.
Prevention and Management of Tardive Dyskinesia
Although preventing TD entirely is challenging due to its unpredictable nature, there are strategies to minimize risk. Healthcare providers often prescribe the lowest effective dose of antipsychotics and urge regular assessments to manage dose adjustments proactively and reduce potential exposure to TD triggers. Moreover, some studies suggest that vitamin E supplements might play a role in reducing the risk when taken with antipsychotic medications.
Why You Should Learn More About Managing Tardive Dyskinesia Today
With an estimated 500,000 individuals in the U.S. affected by tardive dyskinesia, the disorder prompts a critical health concern, primarily among those on antipsychotic medications. Understanding the available treatments, like Abilify and Austedo, and the advancements in FDA-approved options can empower patients and healthcare providers to make informed decisions. As new formulations such as Austedo XR emerge, offering effective and convenient dosing, it is crucial for those affected or treating TD to remain informed. The ultimate goal is to improve patients’ quality of life by enhancing symptom management and creating easier pathways for dealing with the disorder.
Sources
Explore Tardive Dyskinesia Causes and Treatments